Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

PURPOSE: Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC). To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a larg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lara, Primo N., Natale, Ronald, Crowley, John, Lenz, Heinz Josef, Redman, Mary W., Carleton, Jane E., Jett, James, Langer, Corey J., Kuebler, J. Philip, Dakhil, Shaker R., Chansky, Kari, Gandara, David R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2684855/
https://ncbi.nlm.nih.gov/pubmed/19349543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.1061
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars